Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Dominick, Sally ^a   Hickey, Martha ^b   Chin, Jason ^c   Su, H Irene ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KING EDWARD MEMORIAL HOSPITAL   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CONTRACEPTIVE AGENT;

ADJUVANT THERAPY; BREAST CANCER; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DISEASE SURVEILLANCE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPOTTING; SYSTEMATIC REVIEW; UTERUS MYOMA; VAGINA BLEEDING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; INTRAUTERINE CONTRACEPTIVE DEVICE; META ANALYSIS; POLYPS; PREVENTION AND CONTROL; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; NEOPLASM RECURRENCE, LOCAL; POLYPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 84965190484     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007245.pub3     Document Type: Review

References (19)

1. Chan SSC, Tam WH, Yeo W, Yu MMY, Ng DPS, Wong AWY, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen treated women. BJOG 2007;114(12):1510-5.
2. Wong AWY, Chan SSC, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstetrics and Gynecology 2013;121(5):943-50.
3. Gardner FJE, Konje JC, Abrams KR, Brown LJR, Khanna S, Al-Azzawi F, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356(9243):1711-7.
4. Gardner FJE, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using levonorgestrel releasing intrauterine system: Long-term follow-up of a randomised control trial. Gynecologic Oncology 2009;114(3):452-6.
5. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 2008;11(3):252-7.
6. Omar H, Elkhayat W, Aboulkasem M. The use of levonorgestrel-releasing intrauterine system in prevention of endometrial pathology in women with breast cancer treated with tamoxifen. The International Journal of Medicine 2010;3(1):327-330.
7. ACOG Committee Opinion No 336. Tamoxifen and uterine cancer. Obstetrics and Gynecology 2006;107(6):1475-8.
8. Coates AS, Keshaviah A, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 2007;10;25(5):486-92.
9. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecologic Oncology 2004;94(2):256-66.
10. Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381(9869):805-816.
11. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
12. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
14. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A cases control study on hormone therapy as a risk factor for breast cancer in Finland. International Journal of Cancer July 2009;126(2):483-9.
15. Scommegna A, Pandya GN, Christ M, Lee AW, Cohen MR. Intrauterine administration of progesterone by a slow releasing device. Fertility and Sterility 1970;21(3):201-10.
16. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam Pa. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility 2008;90(1):17-22.
17. Van Leeuwen FE, Benraadt J, Coesbergh JW, Kiemeney LA, Gimbrere CH, Otter R. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:1318-21.
18. American Cancer Society. www.cancer.org. www.cancer.org 2008.
19. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41(4):353-62.